|1.||Figg, William D: 14 articles (12/2008 - 01/2003)|
|2.||Dahut, William L: 13 articles (12/2008 - 01/2003)|
|3.||Beer, Tomasz M: 10 articles (01/2009 - 01/2003)|
|4.||Steinberg, Seth M: 8 articles (12/2008 - 07/2004)|
|5.||Jones, Elizabeth: 6 articles (01/2008 - 07/2004)|
|6.||Arlen, Philip M: 6 articles (01/2008 - 01/2003)|
|7.||Gulley, James L: 6 articles (01/2008 - 01/2003)|
|8.||Price, Douglas K: 5 articles (12/2008 - 12/2004)|
|9.||Oh, William K: 5 articles (09/2007 - 07/2003)|
|10.||Kantoff, Philip W: 5 articles (09/2006 - 07/2003)|
|1.||Prostatic Neoplasms (Prostate Cancer)
02/01/2002 - "The formulation may therefore be beneficial in anthracycline-sensitive malignancies, where toxicity represents a major problem, as is the case in androgen-insensitive prostate cancer (AIPC). "
12/06/2007 - "At present there is no effective treatment for androgen-independent prostate cancer (AIPC). "
08/01/2001 - "Novel treatment regimens for androgen-independent prostate cancer (AIPC) are needed because currently available approaches have not been shown to improve survival. "
10/01/2005 - "The primary objective of this study was to determine the clinical efficacy of this agent in the treatment of androgen-independent prostate cancer (AIPC) using PSA and clinical criteria. "
09/01/2008 - "The aim of our study was to analyze the expression profile of several molecular markers that are candidates for targeted therapy in patients with progressive androgen-independent prostate cancer (AIPC). "
06/15/2005 - "In AIPC tumors, expression of Raf-1 correlated significantly with expression of HER2 and with expression of c-fos. "
06/15/2005 - "Protein expression of Raf-1 was analyzed using immunohistochemistry (IHC) in a database of 65 paired tumor specimens obtained before and after the development of AIPC and correlated with other members of the pathway. "
03/01/2003 - "PET measures of tumor blood flow and metabolism may have use in monitoring the physiologic changes occurring during anti-angiogenic therapy in AIPC."
03/01/2002 - "Tumor relapse, defining AIPC, was associated with increased expression of p21 to levels comparable with those found before castration. "
01/01/2012 - "Taken together, we indicated that C42 can induce caspase-dependent apoptosis in AIPC cells, and the results presented here will broaden our knowledge about the molecular mechanisms by which C42 exerts its anticancer activity, and future work in this direction may provide valuable information in the development of these compounds into effective cancer therapeutic strategies against androgen-independent prostate cancer."
|4.||Neoplasm Metastasis (Metastasis)
01/01/2003 - "The significantly prolonged natural course of P-RT patients without distant metastases has to be accounted for in clinical trials of AIPC patients in whom survival represents an endpoint. "
06/01/2008 - "Although androgen levels and androgen synthesis are suppressed in prostatic tissues during the phase of response to endocrine treatment, androgen levels and, specifically, 5-alpha-dihydrotestosterone (DHT) were elevated in tissues derived from metastases of AIPC. "
11/01/2005 - "These results suggest that the C1772T polymorphism in HIF-1alpha may confer susceptibility to AIPC and contribute to the progression or metastasis of this disease."
07/01/1998 - "In a group of 27 patients with limited bone involvement by AIPC (i.e., <3% BSI), the distribution of early metastases was not random within the skeleton but was distributed in the central skeleton in a manner that matched the distribution of the normal adult bone marrow. "
05/15/2009 - "In the current study, 28% of patients with AIPC exhibited an increase in SFK activity in prostate cancer tissue, these patients had significantly shorter overall survival (P<0.0001), and activated SFK expression correlated with the presence of distant metastases. "
06/01/2005 - "The current study was conducted to develop a prognostic model of event-free survival (EFS) in men with androgen-independent prostate carcinoma (AIPC). "
02/15/2001 - "There are limited data available regarding the cost of care in patients with androgen independent prostate carcinoma (AIPC), and there are no data on the impact of direct nonmedical and indirect costs (DNM/IC). "
02/15/2004 - "The current study determined the efficacy and toxicity of weekly paclitaxel in combination with estramustine phosphate (EMP) in patients with androgen-independent prostate carcinoma (AIPC). "
03/01/2002 - "Recent clinical trials have shown antitumor activity with the combination of docetaxel plus estramustine phosphate (EMP) in the treatment of patients with androgen independent prostate carcinoma (AIPC). "
02/15/2005 - "Oral estrogen therapy has activity in patients with hormone-naive and androgen-independent prostate carcinoma (AIPC), but its utility is limited by the associated risk of thromboembolic toxicity. "
|4.||Prostate-Specific Antigen (Semenogelase)
|6.||phenethyl isothiocyanate (PEITC)
|7.||Epidermal Growth Factor Receptor (EGF Receptor)
|9.||Gonadal Steroid Hormones (Sex Hormones)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|5.||Platelet Transfusion (Blood Platelet Transfusions)